The effect of Artemisia herbal cream product on improving the symptoms of patients with psoriasis

Investigation of the safety and efficacy of Artemisia herbal cream product for the improvement and treatment of psoriasis skin patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20080901001157N20

Enrollment

Registered

2023-03-29

Start date

2023-04-03

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Psoriasis. Condition 2: Other psoriasis. Condition 3: Moderate to severe psoriasis. Psoriasis vulgaris Other psoriasis Generalized pustular psoriasis

Interventions

Intervention 1: Intervention group: for 3 weeks, the patients of this group used a 60-gram tube of plant extract cream containing artemisia extract, wheat germ oil, jojoba oil, avocado oil, and pomegr

Eligibility

Sex/Gender

All

Age

15 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with psoriasis. 15 to 50 years old who are able to use the topical product. Personal desire to participate in the project and the signing of a written consent.

Exclusion criteria

Exclusion criteria: People who are allergic to plant extracts and Artemisia annua plant extract. pregnant women. Lactating women. Patients treated for systemic psoriasis 3 months before and during the study. Patients who have a history of malignant disease, taking anti inflammatory and immunosuppressive drugs.

Design outcomes

Primary

Measure	Time frame
Erythema (redness) of Psoriasis rashes. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.;PASI number suitable for each patient (severity index of the psoriasis area). Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: The software for calculating the severity index of psoriasis area version 2.7.1.;The thickness and prominence of psoriasis rashes. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.;Flaking. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.;Level of conflict. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Ruler (cm).;Intensity of itching. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Using a visual scale with scoring by patients from 0 (no itching) to 10 (the most severe itching).;Patient satisfaction. Timepoint: After completing the study. Method of measurement: VAS index (visual analog scale) which is a 10-point scale and shows the quality of the patient in the form of quantity with numbers.	—

Measure

Time frame

Erythema (redness) of Psoriasis rashes. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.;PASI number suitable for each patient (severity index of the psoriasis area). Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: The software for calculating the severity index of psoriasis area version 2.7.1.;The thickness and prominence of psoriasis rashes. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.;Flaking. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Observation.;Level of conflict. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Ruler (cm).;Intensity of itching. Timepoint: At the beginning of the study (before the start of the intervention) and after three weeks (end of the study). Method of measurement: Using a visual scale with scoring by patients from 0 (no itching) to 10 (the most severe itching).;Patient satisfaction. Timepoint: After completing the study. Method of measurement: VAS index (visual analog scale) which is a 10-point scale and shows the quality of the patient in the form of quantity with numbers.

—

Secondary

Measure	Time frame
Side effects of the drug. Timepoint: During the study. Method of measurement: Questionnaire and specialized visit by a dermatologist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasrin Razavianzadeh

Islamic Azad University

nasrinrazavianzadeh@gmail.com+98 23 3223 1442

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026